Retatrutide is an investigational once-weekly injection from Eli Lilly for obesity and type 2 diabetes. It is a triple agonist, meaning it activates three hormone receptors, GIP, GLP-1, and glucagon, one more than tirzepatide (Mounjaro, Zepbound) and two more than semaglutide (Ozempic, Wegovy). It is not yet FDA-approved.

How much weight does retatrutide cause you to lose?

In its phase 2 trial, people lost about 24% of their body weight at the highest dose over 48 weeks. Its larger phase 3 trials, reported in 2025 and 2026, showed roughly 28 to 30% over longer periods, the most reported for any obesity drug so far. These are averages from placebo-controlled trials rather than head-to-head comparisons against other weight-loss drugs.

Is retatrutide FDA-approved?

No. As of mid-2026 it is still investigational and available only through clinical trials. The manufacturer is expected to seek approval around late 2026, which points to a possible approval in 2027 at the earliest. Any retatrutide sold online now as a compounded or research product is unapproved and unverified, and taking it that way is risky.

How is retatrutide different from Mounjaro (tirzepatide)?

Tirzepatide activates two receptors, GIP and GLP-1. Retatrutide activates those two plus a third, the glucagon receptor, which is thought to increase how much energy the body burns. That third action appears to drive greater weight loss, but it also raises heart rate more, which is the main added caution. Tirzepatide is approved and available; retatrutide is still in trials.

Does retatrutide raise your heart rate?

Yes, modestly. The trials showed a dose-dependent increase in heart rate of several beats per minute, linked to the glucagon component, that tended to peak partway through treatment. This is the signal that most distinguishes retatrutide from the single and dual agonists, and it is part of why the long-term heart-outcome trial matters before the drug is used widely.

Retatrutide is an investigational once-weekly injection from Eli Lilly for obesity and type 2 diabetes. It is a triple agonist, meaning it activates three hormone receptors, GIP, GLP-1, and glucagon, one more than tirzepatide (Mounjaro, Zepbound) and two more than semaglutide (Ozempic, Wegovy). It is not yet FDA-approved.

How much weight does retatrutide cause you to lose?

In its phase 2 trial, people lost about 24% of their body weight at the highest dose over 48 weeks. Its larger phase 3 trials, reported in 2025 and 2026, showed roughly 28 to 30% over longer periods, the most reported for any obesity drug so far. These are averages from placebo-controlled trials rather than head-to-head comparisons against other weight-loss drugs.

Is retatrutide FDA-approved?

No. As of mid-2026 it is still investigational and available only through clinical trials. The manufacturer is expected to seek approval around late 2026, which points to a possible approval in 2027 at the earliest. Any retatrutide sold online now as a compounded or research product is unapproved and unverified, and taking it that way is risky.

How is retatrutide different from Mounjaro (tirzepatide)?

Tirzepatide activates two receptors, GIP and GLP-1. Retatrutide activates those two plus a third, the glucagon receptor, which is thought to increase how much energy the body burns. That third action appears to drive greater weight loss, but it also raises heart rate more, which is the main added caution. Tirzepatide is approved and available; retatrutide is still in trials.

Does retatrutide raise your heart rate?

Yes, modestly. The trials showed a dose-dependent increase in heart rate of several beats per minute, linked to the glucagon component, that tended to peak partway through treatment. This is the signal that most distinguishes retatrutide from the single and dual agonists, and it is part of why the long-term heart-outcome trial matters before the drug is used widely.

Retatrutide: The Triple Agonist (GIP/GLP-1/Glucagon) | Philadelphia

TL;DR30-second take

Retatrutide is an investigational weight-loss and diabetes drug from Eli Lilly that activates three gut and metabolic hormone receptors at once, GIP, GLP-1, and glucagon, where Ozempic targets one and Mounjaro targets two. In early trials it produced about 24% weight loss, and its larger phase 3 trials reported in 2025 and 2026 showed roughly 28 to 30%, the most reported for any obesity drug so far. It is not yet FDA-approved. The added glucagon action may burn more energy but also raises heart rate, and the drug has no heart-attack or stroke outcome data yet.

TL;DR: Retatrutide is an investigational drug from Eli Lilly that goes a step beyond the current weight-loss injections. Where semaglutide (Ozempic, Wegovy) targets one hormone receptor and tirzepatide (Zepbound, Mounjaro) targets two, retatrutide targets three: GIP, GLP-1, and glucagon. That third target, glucagon, is thought to raise how much energy the body burns, on top of the appetite effects. In an early trial it produced about 24% weight loss over 48 weeks, and its larger phase 3 trials, which began reporting in late 2025 and 2026, have shown roughly 28 to 30%, the most reported for any obesity drug so far. It also lowers blood sugar and cuts liver fat sharply. The trade-off is that the glucagon action raises heart rate, and as of mid-2026 the drug is still investigational, not yet FDA-approved, with no heart-attack or stroke outcome data.

What is retatrutide, and how is it different from Ozempic and Mounjaro?

Retatrutide is a once-weekly injection that mimics three of the body's metabolic hormones at once. Semaglutide, the drug in Ozempic and Wegovy, acts on a single receptor, GLP-1. Tirzepatide, in Zepbound and Mounjaro, acts on two, GIP and GLP-1. Retatrutide adds a third, the glucagon receptor, which is why it is called a triple agonist.

The first two targets do what the current drugs do: slow the stomach, quiet appetite, and improve how the body handles blood sugar. The third target is the new idea. Glucagon, in this setting, is thought to raise energy expenditure, meaning the body burns more calories, and to help the liver clear its fat. Combining appetite suppression with more energy burned is the mechanism behind retatrutide's unusually large weight loss. It is the same design logic as tirzepatide, taken one hormone further.

How much weight do people lose on retatrutide?

The early numbers drew attention. In its phase 2 obesity trial, adults with obesity and without diabetes lost about 24% of their body weight at the highest dose over 48 weeks, compared with about 2% on placebo.¹ At the time, that was the largest weight loss reported for any drug in a trial.

The larger phase 3 trials, which began reporting in late 2025 and 2026, have pushed the figure higher, into the range of about 28 to 30% at the top dose over the longer treatment periods those trials used. Those results come from the manufacturer's late-stage program and its reported trial readouts, and they represent the most weight loss reported for an obesity drug so far. Two qualifiers belong here. These trials compared retatrutide against placebo rather than head-to-head against tirzepatide or semaglutide, so any ranking against those drugs is a cross-trial inference rather than a direct contest. And the numbers are averages; individual results vary widely.

What about diabetes and liver fat?

Retatrutide is being developed for more than weight. In a phase 2 trial in people with type 2 diabetes, it lowered A1c, the three-month blood-sugar average, substantially, by roughly 2 percentage points at the higher doses, while also producing large weight loss.² That trial compared it against dulaglutide, an established but modestly dosed diabetes drug, and retatrutide outperformed it on both blood sugar and weight.

The liver results are among the most striking. In a phase 2 study of people with metabolic-associated fatty liver disease, retatrutide reduced liver fat dramatically, with most people on the higher doses reaching a normal liver-fat level.³ Because fatty liver is closely tied to metabolic disease and cardiovascular risk, this is a meaningful signal, though it, too, comes from an early-phase study measuring liver fat rather than long-term outcomes. Our fatty liver guide explains why that matters.

The catch: the glucagon trade-off

The third hormone that makes retatrutide powerful also makes it more complicated. Glucagon has effects beyond energy burning, and the trials showed a dose-dependent rise in heart rate, on the order of several beats per minute, that peaked partway through and eased somewhat later. A faster resting heart rate is not trivial over time, and it is the caveat that most sets retatrutide apart from the dual and single agonists.

There is also a question about blood sugar. Glucagon normally raises blood glucose, so adding a glucagon signal could, in theory, work against the goal in a diabetes drug. In the trials, that did not happen on balance: the GLP-1 and GIP effects dominated, and blood sugar fell rather than rose. But the glucagon component is a reason the drug needs careful monitoring, above all early on and in people with diabetes. It is a more active molecule than its predecessors, with more to watch.

Is retatrutide available yet?

It is not yet available as a prescription. As of mid-2026, retatrutide is investigational: it is in the final phase of testing but has not been approved by the FDA. The large phase 3 program, run under the TRIUMPH name for obesity and TRANSCEND for diabetes, has reported strong early results, and the manufacturer is expected to seek FDA approval around the end of 2026, which would put a possible approval no earlier than 2027. Until then, the only legitimate way to take it is inside a clinical trial.

That status matters for a practical reason. Because demand is high and the drug is not yet available, a gray market of compounded or so-called research versions has appeared online. These are unapproved, unverified for purity or dose, and outside medical oversight, and they carry serious risk. The sensible path is to wait for the approved product or to ask about trial enrollment.

One more limit belongs here, stated plainly. All of retatrutide's results so far are weight, blood sugar, and liver-fat measurements. There is no evidence yet that it prevents heart attacks, strokes, or death; the large cardiovascular-outcomes trial that would answer that is underway and not expected to report until around 2028 or later. Semaglutide has that kind of outcome proof today; retatrutide does not, which is a fair difference to keep in mind while the excitement builds.

Guidance from the Clinic

"Retatrutide is the most exciting thing in the metabolic pipeline, and I try to hold that excitement and my caution in the same hand. The weight-loss numbers are extraordinary, better than anything we have prescribed, and the liver-fat results could change how we treat fatty liver. What I keep front and center for patients is that it is not approved yet, and that the compounded versions sold online are a gamble with your health rather than a shortcut. I also pay attention to the heart rate, because the glucagon arm that makes this drug so strong is also the part that raises the pulse, and we do not yet have the long-term heart-outcome data. When it is approved, and I expect it will be, I will use it thoughtfully, with the same rule I apply to every powerful weight drug: protect the muscle, watch the numbers, and make sure the plan is one you can live on."

Key Takeaways

Retatrutide is an investigational triple agonist from Eli Lilly that activates three receptors, GIP, GLP-1, and glucagon, one more than tirzepatide and two more than semaglutide.
The added glucagon action is thought to raise energy expenditure, and it drives the largest weight loss reported for any obesity drug: about 24% in phase 2 and roughly 28 to 30% in the phase 3 trials reported in 2025 and 2026.
It also lowers A1c substantially and reduces liver fat sharply in early trials, with most higher-dose patients reaching normal liver fat.
The main trade-off is a dose-dependent rise in heart rate from the glucagon component; the drug is more active and needs closer monitoring than the single and dual agonists.
As of mid-2026 it is not FDA-approved, has no heart-attack or stroke outcome data yet, and should not be bought from online compounded or research sources; the sound path is a clinical trial or an approved drug for now.

Tirzepatide (Zepbound, Mounjaro) - the approved dual agonist retatrutide builds on
Ozempic vs Metformin - where the single-agonist and foundation drugs fit
CagriSema (Cagrilintide + Semaglutide) - the amylin + GLP-1 combination in the same pipeline
Muscle Loss on GLP-1 Drugs - protecting lean mass during rapid weight loss
Medical Weight Loss - building a durable plan around these drugs
Fatty Liver (MASLD) - where retatrutide's liver benefit fits
Survodutide (GLP-1/Glucagon) - the other glucagon drug, built for the liver
Mazdutide (GLP-1/Glucagon) - the glucagon dual agonist approved in China

Scientific References

Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial." New England Journal of Medicine. 2023;389(6):514-526.
Rosenstock J, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial." Lancet. 2023;402(10401):529-544.
Sanyal AJ, et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial." Nature Medicine. 2024.

Fishtown Medicine | Metabolism

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

Deep-Dive Questions

Most weight-loss drugs work on one side of the energy equation: they reduce how much you eat by quieting appetite and slowing the stomach. The glucagon receptor works on the other side. Activating it is thought to raise energy expenditure, the calories the body burns at rest, and to push the liver to oxidize its stored fat. So retatrutide attacks the problem from both directions at once, cutting intake through the GLP-1 and GIP arms while raising output through the glucagon arm. That combination is the leading explanation for why its weight loss exceeds the dual and single agonists, though the same glucagon activity is what raises heart rate, so the benefit and the caution share a source.

It seems like a contradiction, since glucagon's classic job is to raise blood glucose. The resolution is that retatrutide is more than a glucagon drug; it also carries strong GLP-1 and GIP activity, and those lower blood sugar powerfully by improving insulin release and reducing appetite and weight. In the trials, the net effect was a clear drop in A1c, because the glucose-lowering arms outweighed the glucose-raising one. Still, the balance is a reason the drug is dosed and monitored carefully, and it is one of the questions the larger trials are built to answer with more certainty.

It represents the next rung on a ladder. Semaglutide proved that a single incretin hormone could produce major weight loss; tirzepatide showed that adding a second did better; retatrutide suggests that a third, working by a different mechanism, may do better still. Whether it becomes a first-choice drug will depend on more than the weight numbers: on its heart-rate effect over years, on the cardiovascular-outcome trial, on cost and access, and on how it compares in everyday use to the drugs already approved. For now it is the most powerful agent in development, and a sign of how fast this field is moving, but its place in care is still being written.

The sensible answer is to wait. The versions available now are compounded or research-grade products sold outside the approval system, with no guarantee of what is in the vial or at what dose, and no medical oversight of the heart-rate and metabolic effects that this drug in particular requires. If you are interested, the sound options are to ask about clinical-trial enrollment or to build a plan with an approved drug like tirzepatide or semaglutide now, and revisit retatrutide when it clears approval. A powerful drug deserves a safe path.

Ready when you are